FoxHollow Stock Up 25% In Q3 On SilverHawk Profitability, Merck Deal
This article was originally published in The Gray Sheet
Executive Summary
FoxHollow's stock advanced 25.1% in the third quarter as investors took notice of the firm's first profitable quarter, increased adoption of the company's SilverHawk peripheral vessel plaque excision system and an expanded research agreement with Merck
You may also be interested in...
Device Newcomer And Pharma Giant Expand Partnership
Merck is buying an 11% stake in device maker FoxHollow, expanding a previous agreement to use plaque isolated from patients' arteries for pharmaceutical research
FoxHollow Finds Rinspiration For Cardiac Market Entry Via Kerberos Purchase
FoxHollow's acquisition of the Rinspiration thrombectomy device through its $32 mil. purchase of Kerberos Proximal Solutions provides the firm with immediate access to the coronary market
Candela Looks To Multi-Use Laser Platform To Help Sustain Growth
Medical and aesthetic laser manufacturer Candela plans to launch a "multi-configuration, multi-application" system early next year to help the firm sustain sales growth at or above the 15%-18% range, according to the company